Business Wire

TECKRO

29.9.2021 15:06:05 CEST | Business Wire | Press release

Share
Teckro Launches Next-Generation Clinical Trial Mobile Platform, Giving Site Staff Faster Answers in Fewer Clicks

Teckro, the creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among stakeholders, announces new product capabilities to accelerate site adoption of modern trial practices, making communication even easier at the point of care. A next-generation mobile app gives investigators and site staff answers in fewer clicks, while platform enhancements will result in new studies operational on Teckro in half the time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005472/en/

Toward its vision of engaging every physician in clinical research, Teckro also unveils its “Teckro Powered” site program to establish a community of research sites ready to advance the industry and help shape future product requirements. Today, more than 23,000 research sites around the world rely on the Teckro platform for clinical trials in all therapeutic areas.

“With a critical mass of sites using Teckro, we deepen our commitment to a simple, site-driven experience that allows physicians to easily engage in research without compromising time caring for patients,” says Teckro CEO Gary Hughes. “Sponsors can ease the complexity of clinical trials with a frictionless way to communicate with sites, including when investigators can receive direct guidance from study experts at the point of care.”

First-Of-Its-Kind Site Program: Teckro Powered

“Teckro Powered” is a novel program open to any research site. The program includes a dedicated sandbox to preview Teckro capabilities and input into future requirements. In addition with the program, sites and site networks can:

  • Build a technology-ready brand. Teckro Powered sites are technically savvy. Designated with a program badge on their websites and social media platforms, sites can use this to differentiate themselves and build their reputations as “sites of choice” for sponsors.
  • Expand physician participation in research. Behind the Teckro Powered program is a community of research sites to open a new way to collaborate and advance the industry. With the strength of a Teckro Powered community, the goal is to encourage more physicians to participate in clinical trials, reaching broader, diverse patient populations.
  • Limit impact of staff turnover. Teckro Powered is a way for sites to mitigate disruption from staff turnover. With study resources conveniently hosted in Teckro and accessible from a smartphone, sites can simplify new study member onboarding. A central source for content, communication and collaboration reduces the time to train new staff over the course of a trial.

“The Teckro Powered program fills a gap in the industry,” says Director of Site Strategy Silvina Baudino. “Working with sites for almost 20 years, I know how challenging clinical research can be. Teckro is dedicated to the site experience, which you see in both the new product capabilities and the investment in the Teckro Powered program. We are creating a way for sites to differentiate themselves and participate in a community of research sites.”

Maximizing Sponsor-Site Collaboration

Teckro’s latest platform enhancements go toward solving gaps in communication and easing the burden on site staff. A hub for study content and communication, the new Teckro capabilities include:

  • Next-generation mobile application. The streamlined app provides a simple, mobile-first user experience to support point of care decisions. Based on deep user research, the new mobile application is optimally designed for clinical trial answers in just a couple of clicks. The new Teckro mobile app is now available in the app stores for Apple and Android smartphones.
  • Diverse experts on demand . Teckro is expanding its communication to support more granular groups of experts for different types of site queries. Real-time guidance from those best suited to provide answers eliminates the need for a “switchboard” or for study monitors to operate as a go-between. The feature will be available in the fourth quarter.
  • Increased speed and scale. Underlying platform improvements mean new studies can be added in half the time. This allows sponsors to standardize on Teckro as a resource for their sites to access current study content and communications across trials.

Meet Teckro at the Global Site Solution Summit
Teckro is a sponsor at the upcoming Global Site Solution Summit (October 1-3). Visit us at Booth 716 to see a demo and talk with our experts. You can also request a meeting with Silvina Baudino (Teckro director of site strategy) or Malia Lewin (Teckro global head of strategy) by completing the form on our event page . Silvina will also participate as a panelist in the breakout session “It's Not You, It's Me: How to Manage Long-Term Partnerships” on both October 2 at 1:30 p.m. and October 3 at 9 a.m.

About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need, when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials from biopharma sponsors, including 12 out of the Top 20 pharma companies. Teckro supports all therapeutic areas, all phases, and any trial format ranging from traditional in-clinic, decentralized clinical trials, or a hybrid approach.

More Information

Link:

ClickThru

Social Media:

https://www.facebook.com/teckroofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye